SYNTHESIS OF METFORMIN NANOPARTICLES AND EVALUATION OF INVITRO THERAPEUTIC APPLICATIONS IN TREATMENT OF DIABETES
Main Article Content
Keywords
Metformin, GTT, Metformin nanoparticles, Salivary amylase, Enzyme Kinetics.
Abstract
Metformin is an antidiabetic drug classified as biguanide and used to treat Type II diabetes. Metformin lowers blood glucose levels by inhibiting production of glucose by liver. In this work We aim to synthesize metformin nanoparticles by using bio-minerals sodium and phosphate and due to their presence in the body with low toxicity. Metformin nanoparticles is more efficient in inhibiting salivary amylase than conventional metformin there by preventing the sudden rise or fall in blood levels. Enzyme Kinetics studies with 1mM NPs shown to inhibit salivary amylase up to the time period of 5-6 min potently and after the mentioned time period they inhibit enzyme by reducing the affinity of the substrate towards the enzyme by intermittent dissociation and association preventing sudden rise or fall in blood glucose levels. Nps of 1mM synthesised is Proven to be efficient in controlling blood glucose levels by maintaining sustainability preventing the sudden rise or fall of glucose levels in plasma.
Downloads
References
1. Blonde L, Dipp S, Cadena D.(2018). Combination Glucose-Lowering Therapy Plans in T2DM: Case-Based Considerations. Adv Ther. Jul;35(7):939-965. [PMC free article] [PubMed] 2. American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S73-S85. [PubMed] 3. Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L, Huang Q. (2017). Metformin: a review of its potential indications. Drug Des Devel Ther. ;11:2421-2429. [PMC free article] [PubMed]. 4.Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. (2014) Metformin: from mechanisms of action to therapies. Cell Metab. Dec 02;20(6):953-66. [PubMed] 5. By Robert H. Shmerling, MD, Senior Faculty Editor, Harvard Health Publishing; Editorial Advisory Board Member, Harvard Health Publishing 6. Batandier C, Guigas B, Detaille D, El-Mir MY, Fontaine E, Rigoulet M, et al (2006). The ROS production induced by a reverse-electron flux at respiratory-chain complex 1 is hampered by metformin. J Bioenerg Biomembr. 38:33–42. 10.1007/s10863-006-9003-8 [DOI] [PubMed] [Google Scholar] 7.Viollet B, et al.,(2012). Cellular and molecular mechanisms of metformin: an overview. Clin Sci =. 122:253–70. 10.1042/CS20110386 [DOI] [PMC free article] [PubMed] [Google Scholar] 8..Shaw RJ, et al.(2005) The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 310:1642–6. 10.1126/science.1120781 [DOI] [PMC free article] [PubMed] [Google Scholar] 9..Fullerton MD et al.(2013). Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin. Nat Med. 19:1649–54. 10.1038/nm.3372 [DOI] [PMC free article] [PubMed] [Google Scholar] 10. Foretz M, et al.(2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest. 120:2355–69. 10.1172/JCI40671 [DOI] [PMC free article] [PubMed] [Google Scholar] 11. Madiraju AK et al.(2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 510:542–6. 10.1038/nature13270 [DOI] [PMC free article] [PubMed] [Google Scholar] 12. Ziquan Lv , Yajie Guo (2020).Metformin and Its Benefits for Various Diseases. Front Endocrinol (Lausanne);Vol.11:191. doi: 10.3389/fendo.2020.00191 PMCID: PMC7212476 PMID: 32425881
Article Sidebar
Article Details
Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.